system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
the date SFJ delivers the Program Transfer Notice to PB. For clarity, this Section 3.20 shall not be effective prior to payment to PB of the Initial Development Cost Payment on the Initial Funding Date. ARTICLE 4 DEVELOPMENT COSTS 4.1 Development Costs. SFJ will be obligated to pay or incur up to One Hundred Twenty Million U.S. Dollars ($120,000,000.00) of Development Costs ("Maximum Development Costs") in accordance with the funding schedule set forth in Section 4.2. Any Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020 Development Costs in excess of the sum of the Maximum Development Costs and any Going Concern Funding will be borne by PB. 4.2 Funding Schedule. 4.2.1 Subject to Section 4.2.4 below, SFJ will pay or incur up to a total of $120 million of Development Costs as set forth in the table below and as detailed below, as set forth in Sections 4.2.2 and 4.2.3. For clarity, this Section 4.2.1 sets forth a summary of the payments due under Sections 4.2.2 and 4.2.3 only, and does not create any additional obligation to pay or incur development costs in excess of those obligations set forth in Sections 4.2.2 and 4.2.3. To be paid 45 days after the later of (a) the Effective Date, and (b) the date that PB has obtained the SVB Consent, as set forth in Section 4.2.2(i) To be paid prior to the date of Successful Phase 3 Interim Analysis, as set forth in Section 4.2.2(ii) To be paid after the date of Successful Phase 3 Interim Analysis, as set forth in Section 4.2.3 Total $10 Million Up to $80 Million* At least $20 Million and up to $30Million Up to $120 Million * In addition to initial $10 Million. 4.2.2 Following the Effective Date and prior to the date of first availability of the Phase 3 Interim Data (the "Interim Period"), SFJ shall pay or incur up to $90 million of Development Costs as follows: (i) The initial payment of Ten Million U.S. Dollars ($10,000,000.00) set forth in the table above, to reimburse PB for development costs incurred by PB prior to the Effective Date (the "Initial Development Cost Payment"), shall be payable on the date ("Initial Funding Date") that is forty-five (45) days after the later of (a) the Effective Date, and (b) the date that PB has obtained the SVB Consent. (ii) Following payment to PB of the Initial Development Cost Payment on the Initial Funding Date: (1) SFJ shall promptly pay all Approved Third Party Vendor Costs incurred by SFJ or PB in connection with the Clinical Trials during the Interim Period. (2) SFJ shall pay to SFJ Affiliates the amount of [***] to reimburse such SFJ Affiliates for their internal costs of overseeing the CROs in European Clinical Trial Countries and the SFJ Territory and for the management of the Clinical Trials in European Clinical Trial Countries and the SFJ Territory during the Interim Period (the "SFJ Interim Management Fee"). Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020 (3) SFJ shall pay PB an amount equal to $90 million, less (a) the Initial Development Cost Payment, (b) the SFJ Interim Management Fee, and (c) the Approved Third Party Vendor Costs paid or incurred by SFJ during the Interim Period, (which Approved Third Party Vendor Costs amount shall be estimated and agreed to by the Parties no later than [***]) to be paid pro rata in six (6) equal quarterly payments within [***] after the end of each Calendar Quarter beginning with the Calendar Quarter ending September 30, 2020 through the Calendar Quarter ending December 31, 2021. Notwithstanding anything else contained herein to the contrary, in no event shall SFJ be required to pay or incur Development Costs in excess of $90 million during the Interim Period. If the Development Costs during the Interim Period exceed $90 million, PB shall pay or incur all such excess Development Costs including continuing to provide the PB Services during the Interim Period at the expense of PB unless otherwise agreed to in writing by SFJ. For the avoidance of doubt, if the Successful Phase 3 Interim Analysis is not achieved, SFJ shall have no obligation to pay or incur any further Development Costs. 4.2.3 Following the date of the Successful Phase 3 Interim Analysis and until the end of the Development Term (the "Final Period"): (i) SFJ shall pay to SFJ Affiliates the amount of [***] to reimburse such SFJ Affiliates for their internal costs of overseeing the CROs in European Clinical Trial Countries and the
"""

Extract the exact clause related to "Non-Disparagement" from the excerpt above.

assistant: Not found.